Eye to the Future in Adenomyosis Research

Abstract

Adenomyosis is a poorly understood and clinically underappreciated gynecologic disorder associated with substantial morbidity including dysmenorrhea, pelvic pain, heavy menstrual bleeding, infertility, and poor pregnancy outcomes. Substantial gaps persist in our understanding of essentially all aspects of this disorder – epidemiology, risk factors, pathogenesis, pathophysiology, diagnosis, and treatment. In this article, we summarize current thoughts on future directions in basic, translational, and clinical adenomyosis research.

Keywords

Adenomyosis - research

Publication History

Article published online:
11 December 2020

• References

• 1 Taylor HS, Giudice LC, Lessey BA. et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017; 377 (01) 28-40
• 2 Rogers PA, Adamson GD, Al-Jefout M. et al; WES/WERF Consortium for Research Priorities in Endometriosis. Research Priorities for Endometriosis. Reprod Sci 2017; 24 (02) 202-226
• 3 Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP. et al. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. Am J Obstet Gynecol 2018; 219 (01) 95e1-95e10
• 4 Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000 Res 2019; 8: 8
• 5 Zhai J, Vannuccini S, Petraglia F, Giudice L. Adenomyosis: mechanisms and pathogenesis. Semin Reprod Med 2020; 38: 129-143
• 6 Yeh CC, Su FH, Tzeng CR, Muo CH, Wang WC. Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study. PLoS One 2018; 13 (03) e0194011
• 7 Guo S, Li Z, Yan L, Sun Y, Feng Y. GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity. Drug Des Devel Ther 2018; 12: 1621-1631
• 8 Razavi M, Maleki-Hajiagha A, Sepidarkish M, Rouholamin S, Almasi-Hashiani A, Rezaeinejad M. Systematic review and meta-analysis of adverse pregnancy outcomes after uterine adenomyosis. Int J Gynaecol Obstet 2019; 145 (02) 149-157
• 9 Habiba M, Pluchino N, Petignat P, Bianchi P, Brosens IA, Benagiano G. Adenomyosis and Endometrial Cancer: Literature Review. Gynecol Obstet Invest 2018; 83 (04) 313-328
• 10 Champaneria R, Abedin P, Daniels J, Balogun M, Khan KS. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. Acta Obstet Gynecol Scand 2010; 89 (11) 1374-1384
• 11 Loring M, Chen T, Isaacson K. Symptoms of adenomyosis and overlapping diseases. Semin Reprod Med 2020; 38: 144-152
• 12 O'Shea A, Figueiredo G, Lee S. Imaging diagnosis of adenomyosis. Semin Reprod Med 2020; 38: 119-128
• 13 Acar S, Millar E, Mitkova M, Mitkov V. Value of ultrasound shear wave elastography in the diagnosis of adenomyosis. Ultrasound 2016; 24 (04) 205-213
• 14 Antero MF, Ayhan A, Segars J, Shih I. Pathology and pathogenesis of adenomyosis. Semin Reprod Med 2020; 38: 108-118
• 15 Herndon CN, Aghajanova L, Balayan S. et al. Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis. Reprod Sci 2016; 23 (10) 1289-1303
• 16 Munro MG. Classification and Reporting Systems for Adenomyosis. J Minim Invasive Gynecol 2020; 27 (02) 296-308
• 17 Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol 2020; 27 (01) 27-35
• 18 Marquardt R, Jeong JW, Asgerally T, Fazleabas A. Animal models of adenomyosis. Semin Reprod Med 2020; 38: 170-180
• 19 Gnecco J, Brown A, Kan E. et al. Physiomimetic models of adenomyosis. Semin Reprod Med 2020; 38: 181-198
• 20 Cope AG, Ainsworth AJ, MD Stewart EA. Current and future medical therapies for adenomyosis. Semin Reprod Med 2020; 38: 153-158
• 21 Chen J, Porter AE, Kho K. Current and future surgical and interventional management options for adenomyosis. Semin Reprod Med 2020; 38: 159-169